Evidence map›Paper›PMID 34650551›Full record

ArticleFrontiers in immunology2021

Small Molecule Potentiator of Adjuvant Activity Enhancing Survival to Influenza Viral Challenge.

Tetsuya Saito, Yukiya Sako, Fumi Sato-Kaneko, Tadashi Hosoya, Shiyin Yao, Fitzgerald S Lao, Jonathan Shpigelman, Karen Messer, Minya Pu, Nikunj M Shukla and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 2 countries.

Tetsuya SaitoMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Yukiya SakoMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Fumi Sato-KanekoMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Tadashi HosoyaMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Shiyin YaoMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Fitzgerald S LaoMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Jonathan ShpigelmanMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Karen MesserThe Herbert Wertheim School of Public Health and Longevity, University of California San Diego, La Jolla, CA, United States.
Minya PuThe Herbert Wertheim School of Public Health and Longevity, University of California San Diego, La Jolla, CA, United States.
Nikunj M ShuklaMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Michael ChanMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Paul J ChuMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Howard B CottamMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Tomoko HayashiMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Dennis A CarsonMoores Cancer Center, University of California San Diego, La Jolla, CA, United States.
Maripat CorrDepartment of Medicine, University of California San Diego, La Jolla, CA, United States.
University of California, San Diego · US

Funding

TO IDENTIFY NOVEL ADJUVANT CANDIDATES THAT CAN BE USED TO AUGMENT THE EFFICACY OF HUMAN VACCINES.75N93019C00042 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CARSON, DENNIS · 2019 to 2024
$10.2M
NIAID NIH HHS 75N93019C00042NIAID NIH HHS HHSN272201400051C
6 · The paper itself

Abstract

As viruses continue to mutate the need for rapid high titer neutralizing antibody responses has been highlighted. To meet these emerging threats, agents that enhance vaccine adjuvant activity are needed that are safe with minimal local or systemic side effects. To respond to this demand, we sought small molecules that would sustain and improve the protective effect of a currently approved adjuvant, monophosphoryl lipid A (MPLA), a Toll-like receptor 4 (TLR4) agonist. A lead molecule from a high-throughput screen, (

Indexed as

Adjuvants, ImmunologicAnimalsFemaleInfluenza A virusInfluenza VaccinesLipid AMaleMiceMice, Inbred BALB COrthomyxoviridae InfectionsAdjuvants, ImmunologicInfluenza VaccinesLipid Amonophosphoryl lipid Aadjuvantinfluenza virusmonophosphoryl lipid A, NF-κBToll-like receptor4vaccine

Identifiers

PMID34650551
PMCPMC8505803
OpenAlexW3204760065

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.